Arena Pharmaceuticals Inc (NASDAQ:ARNA) Sellers Rose By 2.11% Their Shorts As Of May 16, 2018

May 16, 2018 - By Nell Hawkins

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Corporate Logo

It was recorded an increase on Arena Pharmaceuticals Inc (NASDAQ:ARNA)’s shorted shares with 2.11%. It was announced in May by FINRA the 3.79 million shorted shares on ARNA. The 3.71 million previous shares are up with 2.11%. With Average volume 926,000, ARNA’s former position will take 4 days to restore. Float short on Arena Pharmaceuticals Inc is 9.68%.

ARNA reached $46.56 during the last trading session after $0.13 change.Currently Arena Pharmaceuticals, Inc. is uptrending after 169.40% change in last May 16, 2017. ARNA has also 544,285 shares volume. ARNA outperformed by 157.85% the S&P 500.

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland.The firm is valued at $2.28 billion. The companyÂ’s proprietary investigational clinical programs include etrasimod , which is in Phase IIb evaluation for ulcerative colitis, as well as is in Phase IIa evaluation for dermatologic extraintestinal manifestations in inflammatory bowel disease, pyoderma gangrenosum, and primary biliary cholangitis; ralinepag that is in Phase IIb evaluation to treat pulmonary arterial hypertension; and APD371, which is in Phase IIa evaluation for the treatment of pain associated with Crohn's disease.Currently it has negative earnings. It has collaboration agreements with Eisai Inc.; Eisai Co., Ltd.; Axovant Sciences Ltd.; and Boehringer Ingelheim International GmbH.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Ratings Coverage

In total 7 analysts cover Arena Pharmaceuticals (NASDAQ:ARNA). “Buy” rating has 6, “Sell” are 0, while 1 are “Hold”. 86% are bullish. 14 are the (NASDAQ:ARNA)’s analyst reports since January 3, 2018 according to StockzIntelligence Inc. On Tuesday, February 27 the stock has “Buy” rating by Citigroup. On Tuesday, March 20 the firm has “Buy” rating by Cantor Fitzgerald given. On Wednesday, March 14 Cantor Fitzgerald maintained Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) with “Buy” rating. The stock rating was maintained by Cantor Fitzgerald with “Buy” on Wednesday, May 9. On Monday, February 26 the firm has “Buy” rating by Cantor Fitzgerald given. On Wednesday, January 17 the firm has “Buy” rating by Leerink Swann given. On Thursday, January 4 Cantor Fitzgerald maintained Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) rating. Cantor Fitzgerald has “Buy” rating and $45.0 target. The stock rating was upgraded by Needham to “Buy” on Tuesday, March 20. On Tuesday, March 20 the company was maintained by Wells Fargo. On Wednesday, April 18 the firm has “Buy” rating given by Cantor Fitzgerald.

For more Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) news posted briefly go to: Globenewswire.com, Seekingalpha.com, Streetinsider.com, Streetinsider.com or Seekingalpha.com. The titles are as follows: “Report: Developing Opportunities within Haemonetics, Arena Pharmaceuticals, Xperi, MoneyGram International, Boot …” posted on May 15, 2018, “Arena Pharmaceuticals’ (ARNA) CEO Amit Munshi on Q1 2018 Results – Earnings Call Transcript” on May 15, 2018, “Arena Pharma (ARNA), Outpost Medicine Enter into Licensing Agreement for Undisclosed Novel Compound” with a publish date: May 01, 2018, “Omega’s 13F Shows Increase in Ocwen (OCN), Synchrony (SYF), United (UAL), Exits Zynga (ZNGA) (More…)” and the last “My 2 Cents On The Ozanimod Saga” with publication date: May 15, 2018.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.